BEGIN:VCALENDAR
PRODID: University of Exeter
VERSION:2.0
BEGIN:VTIMEZONE
TZID:Europe/London
X-LIC-LOCATION:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20190214T143000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20190214T143000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
END:STANDARD
END:VTIMEZONE
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY; CHARSET=UTF-8 :IHR Seminar: PERSEPHONE; 6 vs. 12 months of adjuvant trastuzumab in patients with HER2+ early breast cancer: A cost effectiveness analysis.
UID:exeter_event_8800
URL:http://www.exeter.ac.uk/events/details/?event=8800
DTSTART;VALUE=DATE:20190214T143000
DTEND;VALUE=DATE:20190214T153000
X-MICROSOFT-CDO-ALLDAYEVENT:FALSE
ORGANIZER: MAILTO:
ATTACH: http://www.exeter.ac.uk/events/details/?event=8800
DTSTAMP:20181123T131049
LOCATION:JS07, Smeall
DESCRIPTION; CHARSET=UTF-8 :Speaker: Professor Claire Hulme, Health Economics Group, Institute of Health Research, UEMS
http://www.exeter.ac.uk/events/details/?event=8800
SEQUENCE:0
PRIORITY:5
CLASS:
STATUS:CONFIRMED
TRANSP:TRANSPARENT
X-MICROSOFT-CDO-IMPORTANCE:1
X-Microsoft-CDO-BUSYSTATUS:FREE
X-MICROSOFT-CDO-INSTTYPE:0
X-Microsoft-CDO-INTENDEDSTATUS:FREE
END:VEVENT
END:VCALENDAR